772 related articles for article (PubMed ID: 32245065)
1. Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies.
Medina MA; Oza G; Sharma A; Arriaga LG; Hernández Hernández JM; Rotello VM; Ramirez JT
Int J Environ Res Public Health; 2020 Mar; 17(6):. PubMed ID: 32245065
[TBL] [Abstract][Full Text] [Related]
2. Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors.
Park Y; Moriyama A; Kitahara T; Yoshida Y; Urita T; Kato R
Anticancer Agents Med Chem; 2012 Jul; 12(6):672-7. PubMed ID: 22263793
[TBL] [Abstract][Full Text] [Related]
3. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
4. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.
Okuma HS; Yonemori K
Adv Exp Med Biol; 2017; 1026():271-286. PubMed ID: 29282689
[TBL] [Abstract][Full Text] [Related]
5. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
Mo W; Liu Q; Lin CC; Dai H; Peng Y; Liang Y; Peng G; Meric-Bernstam F; Mills GB; Li K; Lin SY
Clin Cancer Res; 2016 Apr; 22(7):1699-712. PubMed ID: 26546619
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
7. Relapsed triple-negative breast cancer: challenges and treatment strategies.
Guarneri V; Dieci MV; Conte P
Drugs; 2013 Aug; 73(12):1257-65. PubMed ID: 23842749
[TBL] [Abstract][Full Text] [Related]
8. [Triple-negative breast cancer: molecular characteristics and potential therapeutic approaches].
Nowacka-Zawisza M; Krajewska WM
Postepy Hig Med Dosw (Online); 2013 Nov; 67():1090-7. PubMed ID: 24379250
[TBL] [Abstract][Full Text] [Related]
9. Triple Negative Breast Cancer: A Tale of Two Decades.
Ali AM; Ansari JAK; El-Aziz NMA; Abozeed WN; Warith AMA; Alsaleh K; Nabholtz JM
Anticancer Agents Med Chem; 2017; 17(4):491-499. PubMed ID: 27456662
[TBL] [Abstract][Full Text] [Related]
10. Triple negative breast cancer: new therapeutic approaches and BRCA status.
Guney Eskiler G; Cecener G; Egeli U; Tunca B
APMIS; 2018 May; 126(5):371-379. PubMed ID: 29696717
[TBL] [Abstract][Full Text] [Related]
11. An overview of triple negative breast cancer for surgical oncologists.
Sharma S; Barry M; Gallagher DJ; Kell M; Sacchini V
Surg Oncol; 2015 Sep; 24(3):276-83. PubMed ID: 26092709
[TBL] [Abstract][Full Text] [Related]
12. RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.
Liu Y; Burness ML; Martin-Trevino R; Guy J; Bai S; Harouaka R; Brooks MD; Shang L; Fox A; Luther TK; Davis A; Baker TL; Colacino J; Clouthier SG; Shao ZM; Wicha MS; Liu S
Clin Cancer Res; 2017 Jan; 23(2):514-522. PubMed ID: 28034904
[TBL] [Abstract][Full Text] [Related]
13. Emerging targeted therapeutic strategies for the treatment of triple-negative breast cancer.
Kumari L; Mishra L; Patel P; Sharma N; Gupta GD; Kurmi BD
J Drug Target; 2023 Dec; 31(9):889-907. PubMed ID: 37539789
[TBL] [Abstract][Full Text] [Related]
14. Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies.
Khosravi-Shahi P; Cabezón-Gutiérrez L; Custodio-Cabello S
Asia Pac J Clin Oncol; 2018 Feb; 14(1):32-39. PubMed ID: 28815913
[TBL] [Abstract][Full Text] [Related]
15. Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer.
Anders CK; Winer EP; Ford JM; Dent R; Silver DP; Sledge GW; Carey LA
Clin Cancer Res; 2010 Oct; 16(19):4702-10. PubMed ID: 20858840
[TBL] [Abstract][Full Text] [Related]
16. Small Molecule Therapeutics in the Pipeline Targeting for Triple-Negative Breast Cancer: Origin, Challenges, Opportunities, and Mechanisms of Action.
James N; Owusu E; Rivera G; Bandyopadhyay D
Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892472
[TBL] [Abstract][Full Text] [Related]
17. Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies.
Gupta GK; Collier AL; Lee D; Hoefer RA; Zheleva V; Siewertsz van Reesema LL; Tang-Tan AM; Guye ML; Chang DZ; Winston JS; Samli B; Jansen RJ; Petricoin EF; Goetz MP; Bear HD; Tang AH
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32846967
[TBL] [Abstract][Full Text] [Related]
18. The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality.
Papadimitriou M; Mountzios G; Papadimitriou CA
Cancer Treat Rev; 2018 Jun; 67():34-44. PubMed ID: 29753961
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of biological markers as potential therapeutic targets in Saudi women with triple-negative breast cancer.
Sayed-Ahmed MM; Hafez MM; Al-Shabanah OA; Al-Rejaie SS; Aleisa AM; Al-Yahya AA; Alsheikh A; Al Diab AI; Al-Akeely MH
Tumori; 2013; 99(4):545-54. PubMed ID: 24326846
[TBL] [Abstract][Full Text] [Related]
20. BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness.
Domagala P; Hybiak J; Cybulski C; Lubinski J
Int J Cancer; 2017 Apr; 140(7):1545-1550. PubMed ID: 27943282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]